✓ Translated by DotMD AI Clinical Council Source: RMD open • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37094983 ↗

Phase III Randomized Trial: Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study (N = 996)

Original Paper Title: “Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study”

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 996
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.
  • Study Design & Sample: Phase III Randomized Trial published in RMD open (N = 996 human participants).
  • Biostatistical Rigor Score: 93/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in RMD open (2023), this phase iii randomized trial evaluating 996 human participants investigated: To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study. Key clinical takeaway: Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (RMD open, 2023-04-15; N = 996; Rigor 93/100): Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: secukinumab → Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: health-facilities → Condition: health-occupations →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37094983: Phase III Randomized Trial: Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study (N = 996)

3 of 3 Free Questions Remaining